Knockdown of the TGF-β type II receptor attenuates bleomycin-induced pulmonary fibrosis [8], and an antibody targeting TGF-β1 protects against the profibrotic phenotype in vivo [9]. Here, TGFB1 is linked to pulmonary fibrosis.